Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2022-02-14 4:11 pm Sale | 13G | ATEA PHARMACEUTICALS INC AVIR | RA CAPITAL MANAGEMENT L.P. | 0 0% | -5,368,451 (Position Closed) | View |
| 2022-02-14 3:05 pm Sale | 13G | ATEA PHARMACEUTICALS INC AVIR | Cormorant Asset Management LP | 1,679,442 2.02% | -4,731,913 (-73.81%) | View |
| 2022-02-10 4:15 pm Purchase | 13G | ATEA PHARMACEUTICALS INC AVIR | Sommadossi Jean-Pierre | 7,099,999 8.4% | 298,335 (+4.39%) | View |
| 2022-02-09 3:24 pm Purchase | 13G | ATEA PHARMACEUTICALS INC AVIR | VANGUARD GROUP INC | 5,781,882 6.96% | 5,781,882 (New Position) | View |
| 2022-02-09 09:09 am Purchase | 13G | ATEA PHARMACEUTICALS INC AVIR | FMR LLC | 12,465,409 14.999% | 3,879,374 (+45.18%) | View |
| 2022-02-04 4:12 pm Purchase | 13G | ATEA PHARMACEUTICALS INC AVIR | BlackRock Inc. BLK | 5,781,197 7% | 5,781,197 (New Position) | View |
| 2021-12-10 5:08 pm Purchase | 13G | ATEA PHARMACEUTICALS INC AVIR | EcoR1 Capital LLC | 5,376,134 6.5% | 5,376,134 (New Position) | View |
| 2021-09-24 5:15 pm Sale | 13D | ATEA PHARMACEUTICALS INC AVIR | Bain Capital Life Sciences Fund II L.P. | 3,178,532 3.8% | -846,856 (-21.04%) | View |
| 2021-09-03 5:00 pm Sale | 13D | ATEA PHARMACEUTICALS INC AVIR | Bain Capital Life Sciences Fund II L.P. | 4,025,388 4.9% | -757,714 (-15.84%) | View |
| 2021-04-07 4:31 pm Unchanged | 13G | ATEA PHARMACEUTICALS INC AVIR | RA CAPITAL MANAGEMENT L.P. | 5,368,451 6.5% | 0 (Unchanged) | View |
| 2021-03-10 09:46 am Purchase | 13G | ATEA PHARMACEUTICALS INC AVIR | FMR LLC | 8,586,035 10.392% | 2,138,344 (+33.16%) | View |
| 2021-02-16 4:39 pm Purchase | 13G | ATEA PHARMACEUTICALS INC AVIR | RA CAPITAL MANAGEMENT L.P. | 5,368,451 6.5% | 5,368,451 (New Position) | View |
| 2021-02-16 4:19 pm Purchase | 13G | ATEA PHARMACEUTICALS INC AVIR | Morningside Venture Investments Ltd | 6,634,956 8.03% | 6,634,956 (New Position) | View |
| 2021-02-16 3:33 pm Sale | 13G | ATEA PHARMACEUTICALS INC AVIR | Cormorant Asset Management LP | 6,411,355 7.76% | -475,000 (-6.90%) | View |
| 2021-02-10 4:31 pm Purchase | 13G | ATEA PHARMACEUTICALS INC AVIR | Sommadossi Jean-Pierre | 6,801,664 8.2% | 6,801,664 (New Position) | View |
| 2021-02-08 10:15 am Purchase | 13G | ATEA PHARMACEUTICALS INC AVIR | FMR LLC | 6,447,691 7.804% | 6,447,691 (New Position) | View |
| 2020-11-13 4:01 pm Purchase | 13G | ATEA PHARMACEUTICALS INC AVIR | Cormorant Asset Management LP | 6,886,355 8.34% | 6,886,355 (New Position) | View |
| 2020-11-12 4:15 pm Purchase | 13D | ATEA PHARMACEUTICALS INC AVIR | Bain Capital Life Sciences Fund II L.P. | 4,783,102 5.8% | 4,783,102 (New Position) | View |